ArticleFrontiers in oncology2026
Diversion ostomy improves treatment tolerance, conversion surgery, and survival compared with self-expanding metal stenting in initially unresectable obstructive colorectal cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal decompression strategy for patients with initially non-resectable obstructive colorectal cancer undergoing conversion intent treatment remains unclear. This study compared diversion ostomy (DO) and self-expanding metal stent (SEMS) placement. Methods: Data from 115 patients with initially non-resectable obstructive colorectal cancer, who were treated between June 2021 and June 2025, were retrospectively reviewed. Sixty-two patients underwent DO, and 53 underwent SEMS as the initial decompression strategy. After decompression, patients received oxaliplatin and oral capecitabine (i.e., "CAPEOX")- or folinic acid, fluorouracil, and oxaliplatin (i.e., "FOLFOX")-based systemic therapy with targeted therapy, with or without immunotherapy, according to molecular and immunohistochemical findings. Clinical outcomes, nutritional and inflammatory indices, tumor response, subsequent resection, and overall survival (OS) were compared between the two groups. Results: DO was associated with a significantly higher rate of achievement of Colorectal Obstruction Scoring System (CROSS) score 3 than SEMS (85.5% versus [vs.] 47.2%; P<0.001), and a higher number of chemotherapy cycles (median, 6 vs. 2; P<0.001). Post-treatment nutritional and inflammatory profiles were more favorable in the DO group, with higher Prognostic Nutritional Index (≥45) rates and lower platelet-to-lymphocyte and neutrophil-to lymphocyte ratios (all P ≤ 0.005). The objective response and subsequent resection rates were significantly higher in the DO group than that in the SEMS group (69.4% vs. 30.2%; P<0.001), as was the subsequent resection rate (69.4% vs. 30.2%; P<0.001), respectively. Kaplan-Meier analysis revealed significantly longer OS in the DO group, with a median survival of 27.8 vs. 10.3 months (P<0.0001). In multivariate analysis, SEMS remained independently associated with worse OS than DO (hazard ratio 2.231 [95% confidence interval 1.345-3.842; P = 0.001). Conclusions: In patients with initially non-resectable obstructive colorectal cancer treated with conversion intent, DO was associated with better decompression, improved treatment tolerance, higher resection rates, and longer survival than SEMS placement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.